Improved outcome of COVID-19 over time in patients treated with
CAR T-cell therapy: Update of the European COVID-19 multicenter
study on behalf of the European Society for Blood and Marrow
Transplantation (EBMT) Infectious Diseases Working Party (IDWP)
and the European Hematology Association (EHA) Lymphoma Group

J 2024

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

SPANJAART, Anne Mea, Per LJUNGMAN, Gloria TRIDELLO, Juana SCHWARTZ, Nuria MARTINEZ-CIBRIAN et. al.

Základní údaje

Originální název

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Autoři

Vydání

Leukemia, London, SPRINGERNATURE, 2024, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.400 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-024-02336-1

UT WoS

001275219900001

Štítky

14110212

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 8. 2024 09:12, Mgr. Tereza Miškechová

Anotace

V originále

COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.

Citovat

SPANJAART, Anne Mea, Per LJUNGMAN, Gloria TRIDELLO, Juana SCHWARTZ, Nuria MARTINEZ-CIBRIAN, Pere BARBA, Mi KWON, Lucia LOPEZ-CORRAL, Joaquin MARTINEZ-LOPEZ, Christelle FERRA, Di Blasi ROBERTA, Herve GHESQUIERES, Pim MUTSAERS, Friso CALKOEN, Margot JAK, van Doesum JAAP, Joost S P VERMAAT, van der Poel MARJOLEIN, Johan MAERTENS, Massimiliano GAMBELLA, Elisabetta METAFUNI, Fabio CICERI, Riccardo SACCARDI, Emma NICHOLSON, Eleni THOLOULI, Collin MATTHEW, Victoria POTTER, Adrian BLOOR, Caroline BESLEY, Claire RODDIE, Keith WILSON, Arnon NAGLER, Antonio CAMPOS, Soeren Lykke PETERSEN, František FOLBER, Peter BADER, Jurgen FINKE, Nicolaus KROGER, Nina KNELANGE, de la Camara RAFAEL, Marie Jose KERSTEN a Stephan MIELKE. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. Leukemia. London: SPRINGERNATURE, 2024, s. 1-7. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02336-1.

@article{2421646,
   author = {Spanjaart, Anne Mea and Ljungman, Per and Tridello, Gloria and Schwartz, Juana and MartinezandCibrian, Nuria and Barba, Pere and Kwon, Mi and LopezandCorral, Lucia and MartinezandLopez, Joaquin and Ferra, Christelle and Roberta, Di Blasi and Ghesquieres, Herve and Mutsaers, Pim and Calkoen, Friso and Jak, Margot and Jaap, van Doesum and Vermaat, Joost S P and Marjolein, van der Poel and Maertens, Johan and Gambella, Massimiliano and Metafuni, Elisabetta and Ciceri, Fabio and Saccardi, Riccardo and Nicholson, Emma and Tholouli, Eleni and Matthew, Collin and Potter, Victoria and Bloor, Adrian and Besley, Caroline and Roddie, Claire and Wilson, Keith and Nagler, Arnon and Campos, Antonio and Petersen, Soeren Lykke and Folber, František and Bader, Peter and Finke, Jurgen and Kroger, Nicolaus and Knelange, Nina and Rafael, de la Camara and Kersten, Marie Jose and Mielke, Stephan},
   article_location = {London},
   doi = {http://dx.doi.org/10.1038/s41375-024-02336-1},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group},
   url = {https://www.nature.com/articles/s41375-024-02336-1},
   year = {2024}
}

TY  - JOUR
ID  - 2421646
AU  - Spanjaart, Anne Mea - Ljungman, Per - Tridello, Gloria - Schwartz, Juana - Martinez-Cibrian, Nuria - Barba, Pere - Kwon, Mi - Lopez-Corral, Lucia - Martinez-Lopez, Joaquin - Ferra, Christelle - Roberta, Di Blasi - Ghesquieres, Herve - Mutsaers, Pim - Calkoen, Friso - Jak, Margot - Jaap, van Doesum - Vermaat, Joost S P - Marjolein, van der Poel - Maertens, Johan - Gambella, Massimiliano - Metafuni, Elisabetta - Ciceri, Fabio - Saccardi, Riccardo - Nicholson, Emma - Tholouli, Eleni - Matthew, Collin - Potter, Victoria - Bloor, Adrian - Besley, Caroline - Roddie, Claire - Wilson, Keith - Nagler, Arnon - Campos, Antonio - Petersen, Soeren Lykke - Folber, František - Bader, Peter - Finke, Jurgen - Kroger, Nicolaus - Knelange, Nina - Rafael, de la Camara - Kersten, Marie Jose - Mielke, Stephan
PY  - 2024
TI  - Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
JF  - Leukemia
SP  - 1-7
EP  - 1-7
PB  - SPRINGERNATURE
SN  - 08876924
UR  - https://www.nature.com/articles/s41375-024-02336-1
N2  - COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
ER  -

SPANJAART, Anne Mea, Per LJUNGMAN, Gloria TRIDELLO, Juana SCHWARTZ, Nuria MARTINEZ-CIBRIAN, Pere BARBA, Mi KWON, Lucia LOPEZ-CORRAL, Joaquin MARTINEZ-LOPEZ, Christelle FERRA, Di Blasi ROBERTA, Herve GHESQUIERES, Pim MUTSAERS, Friso CALKOEN, Margot JAK, van Doesum JAAP, Joost S P VERMAAT, van der Poel MARJOLEIN, Johan MAERTENS, Massimiliano GAMBELLA, Elisabetta METAFUNI, Fabio CICERI, Riccardo SACCARDI, Emma NICHOLSON, Eleni THOLOULI, Collin MATTHEW, Victoria POTTER, Adrian BLOOR, Caroline BESLEY, Claire RODDIE, Keith WILSON, Arnon NAGLER, Antonio CAMPOS, Soeren Lykke PETERSEN, František FOLBER, Peter BADER, Jurgen FINKE, Nicolaus KROGER, Nina KNELANGE, de la Camara RAFAEL, Marie Jose KERSTEN a Stephan MIELKE. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. \textit{Leukemia}. London: SPRINGERNATURE, 2024, s.~1-7. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02336-1.

Podrobný výpis o publikaci